Innovative Product Launches SEQENS actively develops and commercializes new biotech and pharmaceutical solutions such as PeptiCode HP-9 and AdvensProtect 2-EHG Green, highlighting opportunities to supply complementary high-value ingredients, formulation assistance, or specialized manufacturing capabilities.

Expansion in Personal Care The company's recent focus on launching biobased skincare ingredients and attending international trade fairs like PCHI Guangzhou suggests potential for sales in natural, sustainable actives and preservatives aimed at cosmetic manufacturers seeking eco-friendly solutions.

Strategic Asset Divestment The sale of botanical actives and diagnostics activities to Solabia indicates a strategic shift towards core pharmaceutical manufacturing, presenting opportunities to offer tailored APIs, intermediates, or R&D collaborations to the company's primary growth areas.

Focus on Innovation and R&D With 300 scientists and multiple R&D centers, SEQENS values innovation, offering prospects to partner for advanced research projects, custom ingredient development, or technology licensing that enhance their portfolio and accelerate time-to-market.

Global Manufacturing Footprint Operating 15 manufacturing sites across Europe, North America, and Asia, SEQENS’s extensive network provides opportunities to optimize supply chain solutions, regional partnerships, or bulk ingredient supply agreements for pharmaceutical and specialty ingredient customers worldwide.